Skip to main content

Advertisement

SpringerLink
Log in

PSORIATIC ARTHRITIS

Does psoriasis treatment affect PsA development?

  • News & Views
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

The results of several retrospective studies have reported that systemic treatment in patients with psoriasis reduces the risk of incident psoriatic arthritis (PsA). Although encouraging from a prevention perspective, such studies are limited in their ability to provide a conclusive understanding of PsA risk, preventing a clear picture from emerging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Scher, J. U. et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat. Rev. Rheumatol. 15, 153–166 (2019).

    Article  Google Scholar 

  2. Acosta Felquer, M. L. et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2021-220865 (2021).

    Article  PubMed  Google Scholar 

  3. Gisondi, P. et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2021-219961 (2021).

    Article  PubMed  Google Scholar 

  4. Shalev Rosenthal, Y. et al. Psoriatic arthritis incidence among patients receiving biologic medications for psoriasis: a nested case control study. Arthritis Rheumatol. https://doi.org/10.1002/art.41946 (2021).

    Article  PubMed  Google Scholar 

  5. Haberman, R. et al. Bridging the gaps in the care of psoriasis and psoriatic arthritis: the role of combined clinics. Curr. Rheumatol. Rep. 20, 76 (2018).

    Article  Google Scholar 

  6. Ogdie, A. et al. Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study. Rheumatology https://doi.org/10.1093/rheumatology/keab622 (2021).

    Article  PubMed  Google Scholar 

  7. Ogdie, A. et al. Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis. Arthritis Res. Ther. 23, 252 (2021).

    Article  Google Scholar 

  8. Nguyen, U.-S. D. T. et al. Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. Ann. Rheum. Dis. 77, 119–123 (2018).

    Article  Google Scholar 

  9. Bell, S. et al. Aiming for cure and preventive initiatives in psoriatic disease: building synergy at NPF, GRAPPA, and PPACMAN. Curr. Rheumatol. Rep. 22, 78 (2020).

    Article  Google Scholar 

  10. Hernan, M.A. & Robins, J. M. Causal Inference: What If (Boca Raton: Chapman & Hall, 2020).

Download references

Acknowledgements

The authors wish to acknowledge C. Ritchlin, J. Scher, J. Gelfand and the PAMPA study group dedicated to investigating opportunities in the prevention of psoriatic arthritis.

Author information

Authors and Affiliations

  1. Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, USA

    Joseph F. Merola

  2. Departments of Medicine and Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Alexis Ogdie

Authors
  1. Joseph F. Merola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexis Ogdie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph F. Merola.

Ethics declarations

Competing interests

J.F.M. declares he is a consultant and/or investigator for Abbvie, Amgen, Biogen, BMS, Dermavant, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma and UCB. A.O. declares she has consulted for Abbvie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB and has received grants from Abbvie, Novartis and Pfizer to the University of Pennsylvania and Amgen to the Forward Databank. Her spouse has received royalties from Novartis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Merola, J.F., Ogdie, A. Does psoriasis treatment affect PsA development?. Nat Rev Rheumatol 17, 708–709 (2021). https://doi.org/10.1038/s41584-021-00706-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-021-00706-y

  • Springer Nature Limited

Search

Navigation